AUS
NZ
UK
CA
USA
IND
The ResMed CDI (ASX:RMD) share price has surged by 39.1% since the beginning of 2024, while Netwealth Group Ltd (ASX:NWL) has seen its share price recover, currently sitting 96.9% above its 52-week lows. Both companies represent key players in their respective industries, with ResMed focused on medical technology and Netwealth providing a platform for wealth management. Here's a closer look at each.
ResMed Share Price Performance
Founded in 1989 by Peter Farrell, ResMed began as an Australian company but has since established its headquarters in San Diego, California. ResMed specializes in the development and distribution of cloud-connected continuous positive airway pressure (CPAP) machines designed to treat obstructive sleep apnea (OSA). Although ResMed’s primary listing is on the New York Stock Exchange (NYSE), it also maintains a secondary listing on the Australian Stock Exchange (ASX), allowing Australian investors to participate in the company’s growth.
ResMed operates on a global scale with a workforce of over 10,000 employees and a presence in more than 140 countries. The company’s operations are divided into two key business units: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division focuses on providing advanced CPAP machines for individuals suffering from sleep apnea. This division also caters to patients who require night-time CPAP therapy or those who are dependent on non-invasive or invasive ventilation systems for life support.
In addition to its hardware offerings, ResMed’s SaaS unit delivers software solutions aimed at assisting in out-of-hospital care, specifically targeting durable or home medical equipment (DME/HME) providers. By leveraging its extensive digital health network, powered by its cloud-connected devices, ResMed combines its hardware, such as masks and humidifiers, with SaaS data to generate valuable insights, improve patient outcomes, and help reduce overall healthcare costs.
The company’s ability to combine both technology and medical expertise has positioned it as a leader in the sleep and respiratory care market. This dual focus on hardware and software also allows ResMed to tap into multiple revenue streams, enhancing its growth potential.
Netwealth Group Ltd: Wealth Management in Focus
Netwealth Group Ltd, founded in 1999, operates as a platform-based wealth management business that provides financial advisors with tools to manage client funds. Since its inception, Netwealth has grown its platform significantly, now boasting more than 140,000 account holders as of 2024. The company oversees over $88 billion in funds under administration (FUA), positioning it as a prominent player in the wealth management industry.
Netwealth's success lies in its ability to offer a comprehensive platform that simplifies the process for financial planners to manage client portfolios. This platform provides an array of services that are integral to wealth management, including asset administration, investment management tools, and other essential features designed to streamline financial advisory services.
The company has demonstrated significant growth over recent years, benefiting from increased demand for digital financial services and the rising trend of self-directed investment management. Its platform is not only robust but also scalable, which allows Netwealth to continue expanding its market share in a competitive landscape.
Valuation Metrics and Share Price Performance
In terms of valuation, ResMed’s price-to-sales (P/S) ratio currently stands at 5.09x, compared to its five-year average of 6.13x. This suggests that ResMed shares are currently trading below their historical average in terms of sales multiples. Valuation is a complex exercise and should not be determined by one metric alone, but this information provides insight into how the company is currently valued relative to its past performance.
Netwealth, on the other hand, trades at a higher price-to-sales ratio of 22.73x, surpassing its five-year average of 20.14x. This indicates that Netwealth shares are priced higher than their historical averages, which might suggest strong market expectations for continued growth. While the price-to-sales ratio is one method to gauge valuation, it is important to consider multiple metrics when analyzing a company’s true value.
Final Thoughts
ResMed and Netwealth Group Ltd both operate in sectors that offer significant growth opportunities. ResMed’s leadership in medical equipment and cloud-based health services positions it well for continued expansion in the global healthcare market, particularly as the demand for sleep and respiratory care solutions grows. Netwealth, on the other hand, remains a key player in the wealth management space, supported by strong demand for digital financial services.
While both companies exhibit solid performance, their valuation metrics suggest different market perceptions. ResMed appears to be trading below its historical valuation, while Netwealth's higher price-to-sales ratio could reflect optimism about future growth prospects.
In sum, both ResMed and Netwealth present compelling profiles in their respective industries, and their recent share price movements illustrate the potential for ongoing development. However, understanding the broader context, including market conditions and company-specific factors, remains essential when assessing future performance.
